Treatment of Helicobacter pylori Infection

First-line Treatment Options

The American Gastroenterological Association recommends bismuth-containing quadruple therapy for 14 days as the preferred first-line empirical treatment in areas with high clarithromycin resistance (>15-20%) 1
In areas with low clarithromycin resistance (<15%), the European Helicobacter Study Group suggests PPI-clarithromycin-amoxicillin or PPI-clarithromycin-metronidazole triple therapy for 14 days can be used 1
High-dose PPI (twice daily) increases the efficacy of triple therapy, with an approximate 5% improvement in eradication success when treatment duration is extended from 7 to 14 days 1
The use of 40 mg of rabeprazole or esomeprazole twice daily is recommended for optimal results, rather than pantoprazole 2

After failure of PPI-clarithromycin-containing therapy, the European Helicobacter Study Group recommends either bismuth-containing quadruple therapy or levofloxacin-containing triple therapy 1
Rising rates of levofloxacin resistance should be considered when selecting second-line therapy, with local surveillance of H. pylori antibiotic resistance being mandatory 1

After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing whenever possible, according to the American Gastroenterological Association 3
Rifabutin triple therapy for 14 days is an option for patients who have failed previous treatments, as suggested by the European Helicobacter Study Group 2

In areas of low clarithromycin resistance, the European Helicobacter Study Group recommends PPI-clarithromycin-metronidazole combination may be prescribed 3
In areas of high clarithromycin resistance, bismuth-containing quadruple therapy is preferred, with local surveillance of H. pylori antibiotic resistance being crucial 3

Confirmation of H. pylori eradication should be performed at least 4 weeks after completing treatment, using non-invasive tests such as the urea breath test (UBT) or a laboratory-based validated monoclonal stool test, as recommended by the American Gastroenterological Association 3
Endoscopy-based testing is necessary for patients with complicated peptic ulcer disease, gastric ulcer, and MALT lymphoma, according to the European Helicobacter Study Group 4

The American Gastroenterological Association recommends eradication for all patients with peptic ulcer disease (active or history) 5
First-degree relatives of family members with gastric cancer should also undergo eradication, as suggested by the European Helicobacter Study Group 6
Patients with previous gastric neoplasia treated by endoscopic or subtotal gastric resection, severe pan-gastritis, corpus-predominant gastritis, or severe atrophy should be considered for eradication, according to the European Helicobacter Study Group 6

Antibiotic resistance is the most important factor responsible for the falling success rate of H. pylori eradication treatment, with local surveillance of H. pylori antibiotic resistance being mandatory, as emphasized by the European Helicobacter Study Group 6
Patient compliance is crucial for successful eradication, and avoiding using antibiotics to which the patient has been previously exposed is recommended, according to the American Gastroenterological Association 7

Sucralfate must be discontinued at least 4 weeks before H. pylori testing with urea breath test or stool antigen test to avoid false-negative results, as it can suppress but not eradicate the bacteria 8
The recommended waiting period of at least 4 weeks after stopping sucralfate is critical for accurate H. pylori testing, similar to the timing required after PPI discontinuation 8
Both the urea breath test (UBT) and monoclonal stool antigen test are the recommended non-invasive tests for determining H. pylori status, but timing after medication discontinuation is critical 8

If a patient is currently taking sucralfate for ulcer management and requires H. pylori testing, discontinue it for at least 4 weeks before testing 8
Never perform H. pylori testing while a patient is actively taking sucralfate or within 4 weeks of discontinuation, as the bacterial suppression will yield unreliable results and may lead to missed diagnoses 8

The American College of Gastroenterology recommends bismuth subsalicylate 2 tablets or capsules four times daily 30 minutes before meals, as part of the bismuth quadruple therapy regimen for 14 days 9
The American College of Gastroenterology recommends tetracycline HCl 500 mg four times daily 30 minutes after meals, as part of the bismuth quadruple therapy regimen for 14 days 9
The American College of Gastroenterology recommends metronidazole 500 mg four times daily 30 minutes after meals, as part of the bismuth quadruple therapy regimen for 14 days 9
The American College of Gastroenterology recommends high-dose PPI (esomeprazole or rabeprazole 40 mg) twice daily 30 minutes before meals, as part of the bismuth quadruple therapy regimen for 14 days 9
Rifabutin 150 mg twice daily is recommended as part of the rifabutin triple therapy regimen for 14 days, particularly useful for patients without penicillin allergy who have failed previous treatments 9
The American College of Gastroenterology recommends amoxicillin 1 gram three times daily, as part of the rifabutin triple therapy regimen for 14 days 9
The American College of Gastroenterology recommends esomeprazole or rabeprazole 40 mg twice daily, as part of the rifabutin triple therapy regimen for 14 days 9

The American College of Gastroenterology recommends using esomeprazole 40 mg or rabeprazole 40 mg twice daily, and avoiding pantoprazole due to inferior potency 9
The relative potency differences are clinically significant, with 20 mg esomeprazole equivalent to 32 mg omeprazole 9
The relative potency differences are clinically significant, with 20 mg rabeprazole equivalent to 36 mg omeprazole 9
The relative potency differences are clinically significant, with 40 mg pantoprazole equivalent to only 9 mg omeprazole, which is inadequate 9

The American College of Gastroenterology recommends avoiding concomitant, hybrid, reverse hybrid, or sequential therapies, as they expose patients to antibiotics that provide no therapeutic benefit and only increase global antimicrobial resistance 9
The FDA recommends fluoroquinolones as last-choice options due to serious side effects, including tendon rupture and cartilage damage 9
Clarithromycin triple therapy should only be used with confirmed susceptibility, not empirically 9
Metronidazole triple therapy should only be used with confirmed susceptibility 9
Levofloxacin triple therapy should only be used with confirmed susceptibility 9